Leading NCI-Designated Cancer Centers Across the Country Leverage ConcertAI’s CancerLinQ to Support Personalized, Evidence-Based Quality Care

Key Takeaways

• Wilmot and UCHealth join CancerLinQ, boosting network coverage
• Real‑time quality metrics replace weeks‑long manual reporting
• Access to 11 million‑patient dataset fuels research and trials
• AI‑curated data supports QOPI certification and benchmarking

Pulse Analysis

The oncology landscape is increasingly data‑centric, and real‑world evidence has become a cornerstone for both clinical decision‑making and drug development. ConcertAI’s acquisition of CancerLinQ from ASCO in 2023 set the stage for a rapid expansion of its AI‑powered platform, now drawing longitudinal data from more than 900 sites nationwide. By onboarding the University of Rochester Wilmot Cancer Institute and UCHealth/University of Colorado Anschutz Cancer Center, the network gains two of the nation’s most research‑active, NCI‑designated centers, enriching the diversity and depth of its dataset.

For the participating cancer centers, the partnership translates into immediate operational gains. Both institutions leverage CancerLinQ to automate the collection of quality metrics required for ASCO’s QOPI certification, shifting from labor‑intensive chart reviews to real‑time dashboards that surface performance gaps within days. This capability not only streamlines compliance but also empowers clinicians to compare outcomes across peers, fostering a culture of continuous improvement and more personalized patient care.

Beyond quality assurance, the expanded network fuels large‑scale oncology research. The CancerLinQ Discovery dataset now spans over 11 million de‑identified patient records, offering life‑science companies and academic investigators a robust, longitudinal view of treatment patterns, outcomes, and genomic insights. As AI continues to refine data harmonization and predictive analytics, the platform positions itself as a critical engine for accelerating clinical trial enrollment and generating evidence that can shape future standards of care across the United States.